Evidence map›Paper›PMID 41359127›Full record

ReviewRheumatology international2025

Methotrexate osteopathy in rheumatoid arthritis.

Olga Dorota Lotkowska, Sabine Adler, Armin Zgraggen

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Metabolic bone disorders: what the internist must not overlook].Innere Medizin (Heidelberg, Germany) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olga Dorota LotkowskaClinic for Rheumatology and Immunology, Kantonsspital Aarau, Aarau, Switzerland. olga.lotkowska@gmail.com.ORCID http://orcid.org/0009-0006-2437-4420
Sabine AdlerClinic for Rheumatology and Immunology, Kantonsspital Aarau, Aarau, Switzerland.ORCID http://orcid.org/0000-0002-4194-9146
Armin ZgraggenClinic for Rheumatology and Immunology, Kantonsspital Aarau, Aarau, Switzerland.ORCID http://orcid.org/0009-0000-5724-1604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate (MTX) is one of the most commonly used therapeutic agents for rheumatologic inflammatory diseases and is generally considered a safe medication. Its negative effects on bone mineral density and the occurrence of fractures were first described as side effects of high-dose MTX in pediatric cancer patients. MTX-associated osteopathy in adults receiving moderate or low doses of MTX (up to 25 mg/week) for rheumatic musculoskeletal disorders remains a controversial topic. The pathogenesis and clinical significance of MTX-associated osteopathy are still incompletely understood. Clinically, it presents as atraumatic stress fractures of the distal or proximal tibia and the calcaneus, most often in elderly women with longstanding rheumatic musculoskeletal diseases, particularly rheumatoid arthritis (RA) and reduced bone mineral density. Its characteristic hallmark remains the imaging finding of band- or meander-shaped fractures along the growth plate, which are commonly multiple. The diagnosis is challenging and requires the exclusion of other causes of lower limb pain. Moreover, overlapping risk factors for insufficiency fractures are common and should be carefully investigated. The diagnosis must be made with caution, as the clinical consequences are discontinuation of MTX. In this paper, we describe four female patients with RA who presented with stress, meander-shaped fractures of the calcaneus and tibia (two with multiple fractures), showing rapid clinical improvement after MTX discontinuation, which can be attributed to MTX-associated osteopathy. Additionally, we performed a systematic review of this condition, focusing on its most common clinical and radiological features, as well as the effects of MTX on bone mineral density and fracture risk.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidFractures, StressMethotrexateTibial FracturesAgedAged, 80 and overBone DensityFemaleHumansMiddle AgedTreatment OutcomeAntirheumatic AgentsMethotrexateArthritisInsufficiency fracturesMethotrexateMTX osteopathyOsteoporosisStress fractures

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.